Everything below concerns mobile phase. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Quality control samples are inserted at intervals to monitor accuracy and precision throughout a batch. Blank samples detect contamination, while spiked samples assess recovery from the sample matrix. Calibration standards establish the relationship between detector response and concentration, and control samples are prepared independently from them whenever possible. Laboratories also participate in proficiency testing and maintain audit trails, instrument logs, and reagent records. Ongoing review of control charts can reveal trends before they cause out-of-specification results.
Method validation demonstrates that an HPLC procedure is suitable for its intended purpose. Common validation parameters include accuracy, precision, specificity, linearity, range, limit of detection, limit of quantification, and robustness. Accuracy reflects agreement with a reference value, while precision describes repeatability under defined conditions. Specificity shows whether the method can measure the analyte in the presence of impurities or matrix components. Validation documents are reviewed before a method is used for routine testing or regulatory submissions.
System suitability testing is performed before and during analytical runs to confirm that the instrument and method are working as expected. Typical checks include retention time, peak area precision, resolution between critical pairs, tailing factor, and theoretical plate count. Acceptance criteria are set in the method or pharmacopeial monograph. If a suitability check fails, the run may be rejected and the instrument or sample preparation may need investigation. This practice helps prevent release of data from a system that has drifted out of control.
Data handling and documentation are central to HPLC quality control. Electronic systems should have audit trails that record changes to methods, sequences, and results. Integration parameters, such as peak baseline and threshold, can affect reported areas and must be defined in advance. Out-of-specification results trigger a structured investigation that may include reanalysis, instrument checks, and review of sample preparation. Regulatory inspections often examine raw data, audit trails, and training records to verify that reported results are traceable and reliable.
Method validation establishes that an HPLC procedure is suitable for its intended use. Key parameters include accuracy, precision, specificity, linearity, range, limit of detection, limit of quantitation, and robustness. Accuracy measures agreement with a true or accepted value, while precision describes repeatability and intermediate precision. Specificity confirms that the method measures the analyte without interference from impurities, degradants, or excipients. Validation is documented in a protocol and report, and acceptance criteria are set before experiments begin. Regulatory guidance varies by region, but the general principles are widely harmonized.
| Property | Value | Notes |
|---|---|---|
| Validation parameter | Accuracy | Closeness to a reference value. |
| Validation parameter | Precision | Repeatability or intermediate precision. |
| Validation parameter | Linearity | Proportional response across a range. |
| System suitability check | Resolution | Separation between adjacent peaks. |
| Quality control tool | Control chart | Tracks results over time for trends. |
Separation performance depends on particle size, pore size, column length, and the chemistry of the stationary phase. Smaller particles generally improve efficiency but require higher pressure and suitable instrumentation. The mobile phase often contains buffers and organic solvents that influence retention and selectivity. Testing labs select conditions based on the analytes, sample matrix, and required sensitivity. Method development frequently involves screening several columns and solvent mixtures before a final set of conditions is chosen.
High-performance liquid chromatography is an analytical technique that separates components in a liquid sample by passing them through a packed column under pressure. A pump delivers a mobile phase at a controlled flow rate, and an injector introduces the sample into the stream. Differences in how analytes partition between the mobile phase and the stationary phase cause them to exit the column at different times. Detection then records a signal proportional to the amount of each separated substance. The resulting chromatogram provides retention times and peak areas for identification and quantification.
Instrumentation includes a solvent delivery system, an autosampler, a column oven, and one or more detectors. Reversed-phase columns with chemically modified silica are widely used, but normal-phase, ion-exchange, size-exclusion, and affinity modes exist for specific separations. Detectors may rely on ultraviolet absorbance, fluorescence, refractive index, or mass spectrometry. Column temperature, mobile phase composition, and flow rate are adjusted to improve resolution. System pressure is monitored because rising pressure can indicate column blockage or deteriorating packing.
Reversed-phase chromatography dominates modern HPLC testing, using a nonpolar stationary phase such as chemically bonded octadecyl groups and a polar mobile phase of water mixed with organic solvent. Analytes partition between the mobile and stationary phases according to hydrophobicity. Gradient elution changes the mobile phase composition over time to separate compounds with a wide range of retention. Isocratic elution keeps the composition constant and is simpler for routine assays. Column temperature, pH, and flow rate influence selectivity, peak shape, and retention time, so these parameters are controlled during a validated method.
Detection in HPLC testing commonly relies on ultraviolet-visible absorbance, fluorescence, refractive index, or mass spectrometry. A diode array detector records full spectra across a wavelength range, which helps identify co-eluting peaks. Mass spectrometry provides mass-to-charge ratios and can confirm molecular identity at low concentrations. The choice of detector depends on analyte structure, required sensitivity, and whether quantitation or identification is the goal. No single detector works for every compound, and method development often compares responses before selecting one.
High-performance liquid chromatography is an analytical technique that separates components of a liquid sample by passing it through a packed column under pressure. A pump delivers a mobile phase at a controlled flow rate, and an injector introduces the sample into the stream. Differences in interaction with the stationary phase cause analytes to migrate at different rates. Detectors record elution as peaks, and a data system converts signals into a chromatogram. The method is suited to compounds that dissolve in a liquid and are not volatile enough for gas chromatography.
Reaction of strontium carbonate with titanium dioxide at high temperature produces the desired strontium titanate plus carbon dioxide. If desired, the strontium titanate product can then be formed into a ceramic-like aggregate via sintering.
Sacubitril/valsartan (Entresto/LCZ696), which has been tested against enalapril in patients with heart failure. Sacubitril (AHU-377), a prodrug which is a component of sacubitril/valsartan Sacubitrilat (LBQ657), the active form of sacubitril RB-101, an enkephalinase inhibitor, used in scientific research. UK-414,495 Omapatrilat (dual inhibitor of NEP and angiotensin-converting enzyme) developed by BMS did not receive FDA approval due to angioedema safety concerns. Ecadotril Candoxatril Other dual inhibitors of NEP with ACE/angiotensin receptor were (in 2003) being developed by pharmaceutical companies.
Psylocke is the alias of two connected characters appearing in American comic books published by Marvel Comics, commonly in association with the X-Men. Both characters are depicted as mutants, a subspecies of humans born with an "X-gene" that grants superhuman abilities. In the primary continuity of the Marvel Universe, the first and best-known incarnation of Psylocke is Betsy Braddock (created by Chris Claremont and Herb Trimpe), a British telepath who was introduced as a supporting character for her twin brother Brian in 1976. Betsy adopts the codename "Psylocke" upon joining the X-Men in 1986, and three years later takes on the appearance of a Japanese woman and the abilities of a ninja in a story written by Claremont and illustrated by Jim Lee. This redesign was retroactively revealed in 1993 as the result of a body swap with the ninja assassin Kwannon (created by Fabian Nicieza and Andy Kubert). Following 29 years of publication history, both women were returned to their respective bodies, and Betsy assumed the mantle of Captain Britain from her brother while Kwannon became the second Psylocke. The Ultimate Universe features two versions of Psylocke: Sai and Kanon Sainouchi (both created by Peach Momoko). In addition to their presence in numerous X-related team titles over the decades, both iterations of Psylocke have been featured in various limited series and one-shots. In 1997, Betsy Braddock, as Psylocke, appeared in the 4-issue team-up series Psylocke and Archangel: Crimson Dawn.
Agroecology Alligator farm Certification for Aquaculture Professionals Fisheries science Fishery Industrial aquaculture List of commercially important fish species Maggots used as food for fish Oyster farming Recirculating aquaculture system Resource decoupling
== In transplant rejection == In a transplant procedure, as of an organ or stem cells, MHC molecules themselves act as antigens and can provoke immune response in the recipient, thus causing transplant rejection. MHC molecules were identified and named after their role in transplant rejection between mice of different strains, though it took over 20 years to clarify MHC's role in presenting peptide antigens to cytotoxic T lymphocytes (CTLs). Each human cell expresses six MHC class I alleles (one HLA-A, -B, and -C allele from each parent) and six to eight MHC class II alleles (one HLA-DP and -DQ, and one or two HLA-DR from each parent, and combinations of these). The MHC variation in the human population is high, at least 350 alleles for HLA-A genes, 620 alleles for HLA-B, 400 alleles for DR, and 90 alleles for DQ. Any two individuals who are not identical twins, triplets, or higher order multiple births, will express differing MHC molecules. All MHC molecules can mediate transplant rejection, but HLA-C and HLA-DP, showing low polymorphism, seem least important. When maturing in the thymus, T lymphocytes are selected for their TCR incapacity to recognize self antigens, yet T lymphocytes can react against the donor MHC's peptide-binding groove, the variable region of MHC holding the presented antigen's epitope for recognition by TCR, the matching paratope. T lymphocytes of the recipient take the incompatible peptide-binding groove as nonself antigen. There are various types of transplant rejection that are known to be mediated by MHC (HLA):
Sources: en.wikipedia.org
In women, the breasts overlie the pectoralis major muscles and extend on average from the level of the second rib to the level of the sixth rib in the front of the rib cage; thus, the breasts cover much of the chest area and the chest walls. At the front of the chest, the breast tissue can extend from the clavicle (collarbone) to the middle of the sternum (breastbone). At the sides of the chest, the breast tissue can extend into the axilla (armpit), and can reach as far to the back as the latissimus dorsi muscle, extending from the lower back to the humerus bone (the bone of the upper arm). As a mammary gland, the breast is composed of differing layers of tissue, predominantly two types: adipose tissue; and glandular tissue, which affects the lactation functions of the breasts. The natural resonant frequency of the human breast is about 2 hertz. Morphologically, the breast is tear-shaped. The superficial tissue layer (superficial fascia) is separated from the skin by 0.5–2.5 cm of subcutaneous fat (adipose tissue). The suspensory Cooper's ligaments are fibrous-tissue prolongations that radiate from the superficial fascia to the skin envelope. The female adult breast contains 14–18 irregular lactiferous lobes that converge at the nipple. The 2.0–4.5 mm milk ducts are immediately surrounded with dense connective tissue that support the glands. Milk exits the breast through the nipple, which is surrounded by a pigmented area of skin called the areola. The size of the areola can vary widely among women. The areola contains modified sweat glands known as Montgomery's glands.
They described MDMA as inducing "an easily controlled altered state of consciousness with emotional and sensual overtones" comparable "to marijuana, to psilocybin devoid of the hallucinatory component, or to low levels of MDA". While not finding his own experiences with MDMA particularly powerful, Shulgin was impressed with the drug's disinhibiting effects and thought it could be useful in therapy. Believing MDMA allowed users to strip away habits and perceive the world clearly, Shulgin called the drug window. Shulgin occasionally used MDMA for relaxation, referring to it as "my low-calorie martini", and gave the drug to friends, researchers, and others who he thought could benefit from it. One such person was Leo Zeff, a psychotherapist who had been known to use psychedelic substances in his practice. When he tried the drug in 1977, Zeff was impressed with the effects of MDMA and came out of his semi-retirement to promote its use in therapy. Over the following years, Zeff traveled around the United States and occasionally to Europe, eventually training an estimated four thousand psychotherapists in the therapeutic use of MDMA. Zeff named the drug Adam, believing it put users in a state of primordial innocence. Psychotherapists who used MDMA believed the drug eliminated the typical fear response and increased communication. Sessions were usually held in the home of the patient or the therapist. The role of the therapist was minimized in favor of patient self-discovery accompanied by MDMA induced feelings of empathy.
== Structure == MHC class I molecules are heterodimers that consist of two polypeptide chains, α and β2-microglobulin (B2M). The two chains are linked noncovalently via interaction of B2M and the α3 domain. Only the α chain is polymorphic and encoded by a HLA gene, while the B2M subunit is not polymorphic and encoded by the beta-2 microglobulin gene. The α3 domain is plasma membrane-spanning and interacts with the CD8 co-receptor of T-cells. The α3-CD8 interaction holds the MHC I molecule in place while the T cell receptor (TCR) on the surface of the cytotoxic T cell binds its α1-α2 heterodimer ligand, and checks the coupled peptide for antigenicity. The α1 and α2 domains fold to make up a groove for peptides to bind. MHC class I molecules bind peptides that are predominantly 8-10 amino acid in length (Parham 87), but the binding of longer peptides have also been reported. While a high-affinity peptide and the B2M subunit are normally required to maintain a stable ternary complex between the peptide, MHC I, and B2M, under subphysiological temperatures, stable, peptide-deficient MHC I/B2M heterodimers have been observed. Synthetic stable, peptide-receptive MHC I molecules have been generated using a disulfide bond between the MHC I and B2M, named "open MHC-I".
== Awards and honors == Csaba Horváth Medal of the Connecticut Separation Science Council (2001) Keene P. Dimick Award in Chromatography of the Society of Analytical Chemists of Pittsburgh (1998) Jubilee Award of the International Symposium on Capillary Chromatography (1998) Golden Diploma from Budapest Technical University (1995) Elected Honorary Member, Hungarian Chemical Society (1992) Marcel J. E. Golay Award of the International Symposium on Capillary Chromatography (1992) M. S. Tswett Medal of the Russian Chromatography Society (1991) Pioneer in the Development of Analytical Instrumentation of the first James L. Waters Symposium at the 41st PittCon (1990) National Award in Chromatography of the American Chemical Society (1985) A. J. P. Martin Gold Award of the Chromatography Discussion Group (1982) Anniversary Medal of Tartu University (Estonia, 1981) L.S. Palmer Award of the Minnesota Chromatography Forum (1980) Anniversary M.S. Tswett Chromatography Medal of the All-Union Scientific Council on Chromatography of the USSR Academy of Sciences (1979) M.S. Tswett Award in Chromatography of the International Symposium on Advances in Chromatography (1978)
== History == The band was launched by vocalist Thomas Anselmi and guitarist Christian Thorvaldson, former members of the short-lived and controversial band Slow, with new bassist Eric Marxsen and drummer Pete Bourne. The band was formed in 1987, when Anselmi and Thorvaldson settled on that name after having collaborated under the short-lived band names Mo and Christian Thorvaldson's Freeze-Dried Dog since the demise of Slow. Initially, the band spelled its name as the symbol ©, pronounced as "Circle C". Under that name, they released a self-titled debut album via Geffen Records in 1991. That album sold poorly, and the band was dropped from Geffen. After a few years of struggling to continue in the music industry, they were signed to BMG Music, releasing their second album Love Story in 1996 under the name Copyright. The singles "Transfiguration" and "Radio" were released from that album. Love Story was a shortlisted Juno Award nominee for Best Alternative Album at the Juno Awards of 1998. The album The Hidden World followed in 2001, with the song "Rock Machine" being released as a single. The band disbanded not long after.
Sources: en.wikipedia.org
Exercising regularly, as exercise increases cellular sugar uptake, which decreases excessive insulin release. Avoiding eating meals or snacks composed entirely of carbohydrates; simultaneously ingest fats and proteins, which have slower rates of absorption; Consistently choosing longer lasting, complex carbohydrates to prevent rapid blood-sugar dips in the event that one does consume a disproportionately large amount of carbohydrates with a meal; Monitoring any effects medication may have on symptoms. Low-carbohydrate diet and/or frequent small meals is the first treatment of this condition. The first important point is to add small meals at the middle of the morning and of the afternoon, when glycemia would start to decrease. If adequate composition of the meal is found, the fall in blood glucose is thus prevented. Patients should avoid rapidly absorbed sugars and thus avoid popular soft drinks rich in glucose or sucrose. They should also be cautious with drinks associating sugar and alcohol, mainly in the fasting state. As it is a short-term ailment, a sugar crash that was not caused by injecting too much insulin does not usually require medical intervention in most people. The most important factors to consider when addressing this issue are the composition and timing of foods. Acute (short-term) low blood sugar symptoms are best treated by consuming small amounts of sweet foods, so as to regain balance in the body's carbohydrate metabolism. Suggestions include sugary foods that are quickly digested, such as:
Glucocorticoids: alclometasone, prednisone, dexamethasone, triamcinolone, cortisone Mineralocorticoid: fludrocortisone Vitamin D: dihydrotachysterol Androgens: oxandrolone, oxabolone, nandrolone (also known as anabolic-androgenic steroids or simply anabolic steroids) Oestrogens: diethylstilbestrol (DES) and ethinyl estradiol (EE) Progestins: norethisterone, medroxyprogesterone acetate, hydroxyprogesterone caproate. Some steroid antagonists:
=== Protein stabilization for optimized isolation === Thermofluor pre-screens can be performed that sample a wide range of pH, ionic strength, and additives such as added metal ions and cofactors. The generation of a protein response surface is useful for establishing optimal assay conditions and can frequently lead to improved purification scheme as required to support HTS campaigns and biophysical studies.
== Animal studies == Several studies have shown acute peripheral administration of PYY3-36 inhibits feeding of rodents and primates. Other studies on Y2R-knockout mice have shown no anorectic effect on them. These findings indicate PYY3-36 has an anorectic (losing appetite) effect, which is suggested to be mediated by Y2R. PYY-knockout female mice increase in body weight and fat mass. PYY-knockout mice, on the other hand, are resistant to obesity, but have higher fat mass and lower glucose tolerance when fed a high-fat diet, compared to control mice. Thus, PYY also plays a very important role in energy homeostasis by balancing food intake. PYY oral spray was found to promote fullness. Viral gene therapy of the salivary glands resulted in long-term intake reduction.
Sources: en.wikipedia.org
Method validation is the documented process of showing that an HPLC procedure produces reliable results for a defined purpose. It examines parameters such as accuracy, precision, specificity, linearity, and robustness. Regulators and quality systems often require validation before routine use.
System suitability is a set of checks run on the chromatographic system before sample analysis. It confirms that resolution, peak shape, retention time, and response meet predefined limits. Failure can invalidate the run and trigger corrective action.
Blank injections reveal peaks or baseline disturbances that come from solvents, reagents, or the instrument rather than the sample. They help distinguish contamination from actual analyte signals. Comparing blanks with sample runs supports accurate interpretation.
System suitability is a set of checks that confirm the instrument and method perform within limits before sample analysis. It typically includes resolution, tailing factor, retention time, and peak area reproducibility. If a check fails, the run is invalidated until the cause is resolved.